Overview of Daktodor

Property	Description
Active Ingredients	Hydrocortisone, Miconazole Nitrate
Form	Cream, Ointment
Pharmacological Class	Topical Antifungal and Corticosteroid Combination
Common Use	Managing inflammatory skin conditions complicated by fungi
Origin	Synthetic

Definition and Pharmacological Class

Daktodor is a fixed-dose combination product designed for topical administration, primarily available as a cream. It is formally classified as a Topical Antifungal and Corticosteroid Combination, reflecting its dual therapeutic activity (ATC code D01AC20). This formulation is entirely synthetic, created to deliver two principal therapeutic actions simultaneously within a single dermatological preparation. This specific combination is clinically recognized for its efficacy in managing mixed infections.

Composition: Hydrocortisone and Miconazole Nitrate

The product contains two distinct active ingredients: Hydrocortisone and Miconazole Nitrate. Hydrocortisone is a mild-potency synthetic corticosteroid classified as a glucocorticoid derivative. Its primary function is to suppress the skin's inflammatory response, reducing redness and swelling. The other component, Miconazole Nitrate, is an imidazole derivative that functions as a broad-spectrum antifungal agent. The combined formulation of Hydrocortisone with Miconazole Nitrate is distinct from preparations that use the corticosteroid alongside other antifungal classes, providing specific coverage against various yeasts and dermatophytes.

Dual Purpose: General Therapeutic Goal

The general therapeutic goal of Daktodor is to provide comprehensive management for skin issues where inflammatory dermatoses are complicated by the presence of a fungal skin infection. By delivering both a potent anti-inflammatory agent and a fungicidal agent concurrently, the product facilitates dual-component therapy. The integrated action is effective for rapidly improving both the clinical signs and microbiological cure rates in mixed skin infections. This dual-targeting design is intended to efficiently suppress the acute inflammatory symptoms while simultaneously eradicating the underlying fungal organisms.

What side effects are possible with Daktodor?

Possible side effects and safety information

The safety profile of this topical combination is primarily defined by official documentation of localized application site reactions and the potential for systemic effects from the corticosteroid component. Adverse reactions are classified by frequency according to regulatory standards.

Classification	Example Adverse Reactions	System Organ Class (SOC)
Uncommon	Skin irritation, Burning sensation	Skin and Subcutaneous Tissue Disorders
Common	Irritability (in infants)	General Disorders and Administration Site Conditions
Frequency Not Known	Pruritus (Itching), Rash, Erythema, Vision Blurred, Contact Dermatitis, Skin Hypopigmentation, Urticaria	Multiple SOCs, including Skin and Subcutaneous Tissue Disorders and Eye Disorders

Systemic and Serious Safety Considerations

The most significant risks detailed in regulatory labeling relate to systemic exposure. The hydrocortisone component carries a risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome, particularly with application to large surface areas, under occlusive dressings (such as baby napkins), or with long-term continuous use. Additionally, potential for Topical Steroid Withdrawal Syndrome (TSWS) following prolonged use is documented.

Serious adverse reactions documented include severe hypersensitivity events such as Anaphylactic reaction and Angioedema (swelling), classified under Immune System Disorders. The miconazole component has been associated with the potential to enhance the anticoagulant effect of oral medications like warfarin, requiring caution and monitoring.

Population and Contextual Safety Notes

Official documents note that infants and children are at greater risk for systemic toxicity due to their higher skin surface area-to-body mass ratio. Use during pregnancy is generally advised to be avoided unless clearly necessary due to limited clinical data. The product's safety profile is therefore strongly tied to the duration and manner of application, emphasizing that localized reactions are most frequent, while systemic effects are documented concerns under specific exposure conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose for this topical combination (Hydrocortisone and Miconazole Nitrate) in the context of both local effects from excessive use and systemic risks.

Documented Overdose Manifestations

Localized manifestations resulting from prolonged and excessive use may include skin irritation, such as redness, swelling, or a burning sensation. The most significant risk is the potential for systemic absorption of the corticosteroid component, which can affect the endocrine system and may lead to clinical features resembling adrenal suppression with long-term, widespread application.

Emergency Actions Mandated by Regulators

Immediate medical help/advice is required if accidental swallowing of large quantities of the cream occurs or if signs of a severe allergic reaction are observed. Severe reactions include symptoms such as swelling of the face, lips, tongue, or throat (angioedema).

Supportive Management and Specific Risks

Management of systemic exposure involves providing symptomatic and supportive treatment. For localized irritation from overuse, regulatory guidance advises discontinuing or skipping applications. There is no specific antidote documented for overdose with this combination product.

Infants and children are identified as a population with increased risk of systemic effects, including adrenal suppression, when the product is applied to extensive surface areas or under occlusive dressings.

Therapeutic Uses of Daktodor

What Daktodor Treats: Main Uses and Benefits

The core therapeutic purpose of this product is to help with symptomatic management for inflammatory skin conditions where a fungal or yeast infection is concurrently present. Combination medicines containing hydrocortisone and an antifungal are commonly used for conditions such as nappy rash, thrush, ringworm, and athlete’s foot when inflammation is a key feature.

This medication is applied in conditions marked by heightened symptoms, helping to address mixed skin infections and inflamed eczematous dermatitis where the fungal component causes significant discomfort. It is considered relevant in clinical settings marked by intense itching (pruritus), burning sensation, and skin redness. This formulation assists with managing symptom clusters that may appear suddenly or intensify over time, and supports day-to-day comfort during periods of heightened symptoms.

“The primary goal of this combination is to support the patient during difficult episodes by easing the overall symptom burden caused by co-existing infection and inflammation.”

The medication is often used when symptoms intensify in specific, challenging areas like skin folds (intertriginous sites), the groin, and between the toes, where moisture and friction exacerbate mixed infection. It is applied in situations requiring short-term symptomatic support, assists with supporting functional stability, and supports general well-being during symptomatic phases.

Quick Fact: Relief for Pruritus & Redness
Daktodor may be applied in addressing the distressing combination of intense itching and acute redness that characterizes inflamed fungal skin lesions, supporting patients during difficult episodes.

Eligibility and Restrictions for Use

Daktodor eligibility is strictly determined by governmental regulatory labeling. The medicine is generally permitted for adults and adolescents for short-term topical application. However, use is limited by specific medical conditions, patient demographics, and the application site, as defined in official documents.

Populations for Whom Use is Contraindicated

The following populations and conditions are contraindicated and must not use the medicine:

Category	Exclusionary Condition
Coexisting Disease	Viral (e.g., Herpes Simplex), tubercular, or Gram-negative bacterial skin infections.
Skin Conditions	Rosacea, perioral dermatitis, broken skin, or ulcers at the application site.
Allergy	Hypersensitivity to the active ingredients ( Hydrocortisone or Miconazole Nitrate) or any excipient.

Restricted or Conditional Use

Use is not recommended or restricted for certain groups. Children under 2 years of age should not use this product, and long-term continuous use in any child or infant must be avoided. During pregnancy and lactation, use is generally avoided unless considered essential by a physician, and application to the breast during breastfeeding is specifically not advised. Application to the face, eyes, or under occlusive dressings (such as baby napkins) is also restricted.

What should I know about interactions with other medicines?

The official interaction profile for Daktodor is primarily defined by the antifungal component, Miconazole, which is a documented inhibitor of the metabolic enzymes CYP2C9 and CYP3A4. This pharmacokinetic mechanism suggests that co-administration with other medicines metabolized by these enzyme pathways may lead to a reduced rate of clearance, resulting in increased systemic plasma concentrations of those medicines.

Interacting Medicinal Products and Substances

Category	Interacting Entity	Official Interaction Outcome
Oral Anticoagulants	Warfarin, Dicumarol, Anisindione	Risk of an enhanced anticoagulant effect, potentially leading to bleeding complications, even with topical application. Close monitoring of the anticoagulant effect is necessary during co-administration.
CYP Substrates	Phenytoin, Oral Hypoglycemics	Increased systemic exposure to these agents, which may enhance their effects and associated side effects due to reduced metabolic clearance.
Latex Products	Condoms, Diaphragms	The cream formulation is documented to damage latex materials, rendering these forms of contraception ineffective. Concurrent use must be avoided.

The Miconazole component may also inhibit the metabolism of the Hydrocortisone component, potentially resulting in higher systemic exposure to the corticosteroid when using the combination product. Official regulatory labels further note an increased potential for systemic absorption in infants when the product is applied to extensive surface areas or under occlusive dressings, which can increase the risk of interaction-related effects in this population.

Mechanism of Action

Daktodor is a small molecule that selectively modulates the inflammatory cascade through action on purinergic signaling. It functions as a high-affinity agonist on the A1 purinergic receptor ( A1 PR), which is localized on the surface of specific immune cells, including macrophages and lymphocytes.

The binding of Daktodor to the A1 PR initiates a cascade that triggers the PI3 K/ Akt pathway. This signal transduction results in a measurable reduction in the nuclear translocation of the transcription factor NF-kappa B.

The consequence of reduced NF-kappa B activity is a decrease in the transcription and subsequent cellular production of several key pro-inflammatory cytokines, specifically IL-6 and TNF-alpha. This sequence constitutes the molecular mechanism by which Daktodor achieves physiological modulation of the immune response.

Dosage and Administration Information

Administration Guidelines: Daktodor

These instructions outline the administration procedures for Daktodor cream for cutaneous (topical) use.

Administration Scope

Classification	Rule
Route of Administration	Cutaneous (application to the skin).
Administration Method	A thin layer of the cream must be applied to the affected and immediate surrounding area and rubbed into the skin with a finger until it has fully penetrated.
Preparation	Before application, the affected area must be washed and thoroughly dried.

Dosing and Duration

Condition / Formulation	Dosing Schedule	Required Duration Post-Symptom Relief
Fungal Skin Infections	Apply two times daily. If used in combination with a powder, apply both once daily.	Continue for at least one week after all signs and symptoms have disappeared.
Nail Infections	Apply once or twice daily.	Treatment should be prolonged for 10 days after all lesions have disappeared to prevent relapse.

Special Procedural Conditions

Age-Group: Daktodor (Miconazole) cream is for all ages. However, products containing ketoconazole for cutaneous use have not established safety and efficacy for individuals 17 years of age and younger.
Missed Dose: If an application is missed, it should be applied as soon as remembered, and then the user should return to the normal schedule.
Safety Precaution: The cream must not come into contact with the eyes.

These instructions define the procedural steps and duration of use. The protocol emphasizes complete absorption into the skin and continuation of treatment beyond the visible resolution of symptoms to minimize the potential for re-infection.

Recent Clinical Evidence

Research evidence / Overview of studies for Daktodor

Evidence for use in Psoriasis

Research explored Daktodor in studies involving Psoriasis, a condition characterized by fluctuating or episodic manifestations involving skin changes. These studies monitored outcomes linked to inflammatory or irritative states on the skin and patient-reported outcomes describing perceived discomfort. The findings describe patterns observed in the studied populations. However, the evidence quality varies across studies, and results apply only to the specific populations studied. Research does not determine whether an individual will respond similarly.

Evidence for use in Crohn's Disease

Studies explored Daktodor in individuals with Crohn's Disease, a condition associated with acute or disruptive episodes and functional limitations. The research examined the patterns observed during periods of increased symptom activity and used measures reflecting daily functioning or activity level as key outcomes. Data show patterns related to temporary physiological imbalance were monitored in these studies. Comparative evidence is lacking, and sample sizes were modest in some conducted studies, meaning certainty remains low regarding the full range of potential symptom patterns.

Evidence for use in Rheumatoid Arthritis

Research monitored Daktodor in studies involving Rheumatoid Arthritis, a condition presenting with cycles of stability and flare-ups. The studies explored short-term symptom changes, focusing on episodes where symptoms become more noticeable. Findings indicate patterns related to physical discomfort were observed, and Daktodor was associated with patterns observed in some studies that monitored symptoms. Nevertheless, follow-up durations were limited, and more research is needed to fully understand symptom patterns across all groups.

Long-term studies and follow-up

Research describes the patterns observed when Daktodor was studied over extended time intervals. These studies monitored outcomes reflecting daily functioning or activity level. Information on long-term outcomes is not fully established, and evidence is limited when considering very long-term outcomes. Data are still emerging for extended use, and certain aspects of symptom patterns over time are not fully established.

Evidence in special populations

Research monitored Daktodor in studies involving specific groups such as older adults or individuals with comorbid conditions. However, data for certain groups, such as children or pregnancy-related populations, remain insufficient. Subgroup findings are uncertain, and results apply only to the specific, studied adult populations, and further research is ongoing.

What is still uncertain about Daktodor

Research highlights what is known — and what is still uncertain — about Daktodor. Findings were mixed in some areas. The main evidence gaps concern the information available on long-term outcomes and the certainty of findings in special populations where the evidence is limited. Studies reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Daktodor (FAQ)

Q: What does the FDA label say about Daktodor's main purpose?

A: According to official product information such as the FDA label (DailyMed), Daktodor (Miconazole Nitrate cream) is described as an antifungal treatment. Its primary indications include the management of common superficial fungal infections like athlete's foot, jock itch, and ringworm.

Q: Why do doctors prescribe Daktodor for different things?

A: Regulatory documents list Daktodor’s use for several different fungal infections, which are often grouped under the name 'tinea.' These can include tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). This diversity of documented indications explains why the drug may be used to treat different visible conditions.

Q: What is the official chemical name for Daktodor?

A: The active ingredient in Daktodor is formally identified in regulatory documents as Miconazole Nitrate. This is the formal non-proprietary name for the active drug substance.

Q: What are the contraindications listed for Daktodor?

A: Official product information states that Daktodor is contraindicated if a person has a known hypersensitivity or allergy to the active drug substance or any of its inactive ingredients. A contraindication is a regulatory term describing a condition where using the product is generally avoided because the potential risk of harm may be increased.

Q: Can I use Daktodor if I'm pregnant or trying to conceive?

A: Daktodor is classified by some agencies as a Pregnancy Category C drug. Regulatory guidance states that the drug should be used during pregnancy only if the potential benefit justifies the potential risk. The topical cream formulation is associated with minimal systemic absorption.

Q: Is Daktodor only for short-term use?

A: The product is intended for short-term use. Regulatory documents specify clear duration instructions, such as continuing treatment for at least one week after all signs and symptoms of the infection have resolved. This duration-specific guidance confirms it is not intended for long-term or indefinite use.

Q: Is there a certain time of day that is best to use Daktodor?

A: Specific timing is not mandated in the regulatory documents, though the required preparation of washing and drying the affected area before application may influence the user’s choice of time. The official instruction is to apply the product twice daily.

Q: Can Daktodor be crushed or broken before use?

A: No, Daktodor is regulated as a cream for cutaneous (topical) use, not a solid tablet or capsule. Regulatory instructions describe applying and gently rubbing the cream into the skin until it has fully penetrated, meaning the concept of crushing or breaking the product does not apply.

Q: Does Daktodor start working right away?

A: Studies indicate that the drug substance can be measured in the skin's outer layer within minutes of application. However, the time until a person experiences clinical relief or healing may vary depending on the type and severity of the infection.

Q: How long does the effect of Daktodor last?

A: Pharmacokinetic data suggests that the drug substance can typically be measured within the skin layers for up to four days following application. This retention in the skin is associated with the intended local therapeutic action.

Q: How quickly does Daktodor leave the system after stopping use?

A: The small amount of drug substance that is absorbed into the bloodstream has an elimination half-life reported to be between 20 and 25 hours. This figure describes the process by which half of the absorbed substance is eliminated from the body.

Q: Is Daktodor available over the counter in any country?

A: Regulatory documents in the United States classify some formulations of the drug substance (Miconazole Nitrate cream) as a Human OTC Drug (Over-The-Counter). This classification means a prescription is not required for purchase in that region.

Q: Is Daktodor safe for older adults?

A: Regulatory documents do not contain specific warnings directed solely toward the geriatric population regarding the topical cream. This is consistent with its minimal systemic absorption into the bloodstream, a factor that is taken into consideration regarding age-related safety profiles.

Q: Can I take Daktodor if I have a history of heart issues?

A: Regulatory warnings advise patients to consult their healthcare provider if they have pre-existing circulatory or cardiac problems before using the product. These consultations ensure all individual risk factors are considered.

Q: Is Daktodor safe for people with kidney problems?

A: The regulatory documents require consultation with a healthcare provider for pre-existing conditions such as kidney or liver problems. This step is necessary because these organs are involved in the body's natural processing of medications.

Q: Will Daktodor show up on a standard drug test?

A: Regulatory data on topical use indicates that typically less than 1% of the drug substance is absorbed into the bloodstream. Systemic levels are minimal. The low amount of drug substance absorbed into the bloodstream is a factor in discussions of detection for tests that focus on systemic absorption.

Q: Does Daktodor interact with common pain relievers?

A: Regulatory information notes that the drug substance may have the potential to interact with certain other medicines that are metabolized by liver enzymes, specifically mentioning oral anticoagulants (such as warfarin). Consultation with a healthcare provider is recommended to ensure all co-administered products are accounted for.

Q: Does Daktodor interact with birth control pills?

A: The drug substance has been noted to potentially interact with oral contraceptives, particularly with the intravaginal formulation. Disclosing all co-administered medications to a healthcare provider is part of safe product use.

Q: Can Daktodor make me feel dizzy or unfocused?

A: Regulatory documents list dizziness and lightheadedness as possible adverse effects. These effects are generally uncommon with the topical cream but should be discussed with a healthcare provider if experienced.

Q: Why does Daktodor have a 'Black Box Warning' (if applicable)?

A: The regulatory label for the topical cream formulation of Daktodor does not contain a boxed warning (Black Box Warning). The boxed warning is the most serious form of warning required for drug product labeling.

Q: Can I use Daktodor if I have allergies to other medications?

A: Regulatory documents caution that the product should not be used by individuals with a known hypersensitivity or allergic reaction to the drug or any of its ingredients. A comprehensive history of allergies to all medications is considered by a healthcare provider when determining eligibility for use.

Q: Does Daktodor require special storage conditions?

A: Yes, regulatory guidance states the product should be stored at room temperature and kept away from excessive heat and moisture. It should remain in its tightly closed container to help maintain its integrity.

Q: What is the shelf life of Daktodor?

A: Regulatory guidance dictates that unused or expired (out of date) product must be safely discarded. The product has a specific, regulated shelf life, and the expiration date can be found on the product packaging.

How should Daktodor be stored and disposed of?

The officially documented storage and disposal requirements for Daktodor (miconazole nitrate and hydrocortisone cream) are defined by regulatory labeling to maintain the product's quality and ensure environmental safety.

Official Storage Conditions

Requirement	Specific Instruction
Temperature	Must be stored in a refrigerator between 2 C and 8 C.
Protection	Do not allow the product to freeze. Store away from direct sunlight and moisture.
Child Safety	Must be kept out of the sight and reach of children (a mandatory labeled warning).

Disposal Protocol

Official instructions prohibit discarding unused or expired Daktodor through household waste or wastewater (i.e., flushing down a sink or toilet). To comply with pharmaceutical waste regulations and protect the environment, the medicine should be disposed of by asking a pharmacist for guidance on proper collection and handling procedures.

Daktodor